

15 November 2016

Receipt of R&D Tax Incentive payment

Antisense Therapeutics Limited (“ANP” or “the Company”) would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive payment of \$395,598 in relation to expenditure incurred on eligible R&D activities for the 30 June 2016 financial year.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Ionis Pharmaceuticals Inc. (formerly Isis Pharmaceuticals Inc.), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug targeting the growth hormone receptor which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999